Does one year of training with FES have impressive beneficial effects in a 36-year-old woman with spinal cord injury?
These impressive improvements demonstrate that FES training offers several interesting clinical benefits in a patient with SCI.
This methodology successfully identified a reproducible baseline predictor of differential response to dapagliflozin. Although baseline FPG was shown to be a predictor, the effect size was not of sufficient magnitude to suggest clinical usefulness in identifying patients who would uniquely benefit from dapagliflozin treatment. The findings do support potential benefit for dapagliflozin treatment that is consistent with current recommended use.